Why the study?
Does weight-based enoxaparin dosing result in similar pharmacokinetics and pharmacodynamics in obese compared to nonobese volunteers?
Population
48 volunteers (24 obese and 24 age-, sex-, and height-matched nonobese volunteers)
Comparison
Enoxaparin administered subcutaneously and in a… vs Nonobese volunteers receiving the same…
Design
RCT, randomized, 2-way crossover design, open-label
Follow-up
4 days (subcutaneous) and 6 hours (infusion)
Authors
Loading...
Supports weight-based enoxaparin dosing without adjustment in obesity; reinforces similar pharmacodynamic effects in obese and nonobese individuals.
Does weight-based enoxaparin dosing result in similar pharmacokinetics and pharmacodynamics in obese compared to nonobese volunteers?
Weight-based dosing of enoxaparin (1.5 mg/kg) is well tolerated and provides similar pharmacodynamic effects in obese and nonobese individuals, suggesting no need for dose modification.
Sanderink et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: